Study, year Study design Follow-up Treatment Control Clinical outcome Patients No. of patients ox-LDL MDA-LDL van Tits et al., 2006 [29 ] Randomized double-blind study 2 years A 80 mg/day S 40 mg/day Significant decrease in plasma level of ox-LDL — Patients with heterozygous familial hypercholesterolemia 115 Puccetti et al., 2011 [45 ] Prospective, randomized, double-blind study 8 weeks A 20 mg/day R 10 mg/day Significant decrease in plasma level of ox-LDL — Hypercholesterolemic patients 60 Tsutamoto et al., 2011 [38 ] Randomized double-blind open-label study 6 months A 5 mg/day R 2.5 mg/day Significant decrease in plasma level of ox-LDL in the A group but not in the R group — CHF patients with dilated cardiomyopathy 63 Aydin et al., 2015 [37 ] Randomized active-controlled study 4 weeks A 80 mg/day R 20 mg/day Significant decrease in plasma level of ox-LDL — STEMI 90 Altunkeser et al., 2019 [42 ] Randomized active-controlled study 4 weeks A 80 mg/day R 40 mg/day Significant decrease in plasma level of ox-LDL — ACS 106 Tunçez et al., 2019 [43 ] Randomized active-controlled study 4 weeks A 80 mg/day R 40 mg/day Significant decrease in plasma level of ox-LDL — AMI 63 Gavazzoni et al., 2017 [36 ] Single-center, prospective, randomized, blinded open-label study 1 month A 80 mg/day A 20 mg/day Significant decrease in plasma level of ox-LDL — STEMI 52 Soran et al., 2018 [31 ] Double-blind randomized study 12 months A 80 mg/day A 10 mg/day Significant decrease in plasma level of ox-LDL — T2DM with microalbuminuria or proteinuria 119 Huang et al., 2012 [44 ] Double-blind randomized study 12 months A 40 mg/day A 10 mg/day Significant decrease in plasma level of ox-LDL — Patients with ischemic cardiomyopathy 95 Tamura et al., 2003 [34 ] Randomized crossover study 8 weeks A 10 mg/day P 10 mg/day — Significant decrease in plasma level of MDA-LDL Hypercholesterolemic patients 34 Tsutamoto et al., 2009 [39 ] Randomized active-controlled study 4 months S 5 mg/day R 2.5 mg/day Significant decrease in plasma level of ox-LDL in the R group but not in the S group — Patients with nonischaemic CHF 71 Moutzouri et al., 2013 [30 ] Prospective, randomized, open-label, blinded endpoint study 12 weeks S 40 mg/day R 10 mg/day Significant decrease in plasma level of ox-LDL — Hypercholesterolemic patients 100 Significant decrease in plasma level of ox-LDL Hypercholesterolemic patients 108 Inami et al., 2004 [40 ] Prospective, randomized active-controlled study 12 weeks P 10 mg/day F 20 mg/day Significant decrease in plasma level of ox-LDL — Hypercholesterolemic patients 16 Toribio et al., 2017 [32 ] Double-blind, active-controlled, parallel-group comparative study 52 weeks Pi 4 mg/day P 40 mg/day Significant decrease in plasma level of ox-LDL — HIV-infected patients with dyslipidemia 192 Pesaro et al., 2012 [33 ] Randomized, double-blind, active-controlled study 6 weeks S 80 mg/day Significant decrease in plasma level of ox-LDL — CAD 78 Uemura et al., 2012 [35 ] Randomized open-label crossover study 12 weeks A 20 mg/day — Decrease in plasma level of MDA-LDL Abnormal glucose tolerance and CAD 39 Wu et al., 2018 [46 ] Randomized active-controlled study 12 weeks A 40 mg/day Significant decrease in plasma level of ox-LDL — ASCVD 98 Torimoto et al., 2013 [41 ] Randomized open-label study 12 weeks R 5 mg/day — Significant decrease in plasma level of MDA-LDL T2DM 75 Sakuma et al., 2019 [47 ] Randomized crossover study 3 months Double dose of statin — Significant decrease in plasma level of MDA-LDL CAD 42 Takase et al., 2017 [48 ] Multicenter, prospective, randomized, open-label, blinded-end point study 6-8 months Statin monotherapy — Significant change in plasma level of MDA-LDL CAD patients after coronary stenting 258
